Check Your Eligibility If you want to learn whether GLP-1 treatment is right for you and receive personalized guidance from providers who understand managing weight loss in people with thyroid conditions, you can start by completing Mochis eligibility questionnaire
For weight management , NICE-recommended and licensed options include: Semaglutide (Wegovy) a licensed GLP-1 receptor agonist approved by the MHRA for chronic weight management
This action reduces hunger and food intake, leading to weight loss
What to Expect During Treatment Early weeks may include nausea, bloating, or constipation
Retatrutide belongs to a newer class of investigational metabolic peptides designed to engage multiple receptor pathways simultaneously, rather than targeting GLP-1 alone
Retatrutides available readout, though singular, outperforms tirzepatides best Phase-3 ceiling at a shorter observation window